Adipokines, adiposity, and atherosclerosis

Cell Mol Life Sci. 2022 May 3;79(5):272. doi: 10.1007/s00018-022-04286-2.

Abstract

Characterized by a surplus of whole-body adiposity, obesity is strongly associated with the prognosis of atherosclerosis, a hallmark of coronary artery disease (CAD) and the major contributor to cardiovascular disease (CVD) mortality. Adipose tissue serves a primary role as a lipid-storage organ, secreting cytokines known as adipokines that affect whole-body metabolism, inflammation, and endocrine functions. Emerging evidence suggests that adipokines can play important roles in atherosclerosis development, progression, as well as regression. Here, we review the versatile functions of various adipokines in atherosclerosis and divide these respective functions into three major groups: protective, deteriorative, and undefined. The protective adipokines represented here are adiponectin, fibroblast growth factor 21 (FGF-21), C1q tumor necrosis factor-related protein 9 (CTRP9), and progranulin, while the deteriorative adipokines listed include leptin, chemerin, resistin, Interleukin- 6 (IL-6), and more, with additional adipokines that have unclear roles denoted as undefined adipokines. Comprehensively categorizing adipokines in the context of atherosclerosis can help elucidate the various pathways involved and potentially pave novel therapeutic approaches to treat CVDs.

Keywords: Adiponectin; Adipose tissue; Cardiovascular diseases; Leptin; Obesity.

Publication types

  • Review

MeSH terms

  • Adipokines / metabolism
  • Adiponectin / metabolism
  • Adiposity
  • Atherosclerosis* / metabolism
  • Cardiovascular Diseases*
  • Humans
  • Interleukin-6 / metabolism
  • Leptin / metabolism
  • Obesity / metabolism

Substances

  • Adipokines
  • Adiponectin
  • Interleukin-6
  • Leptin